Skip to content
Screener

Novavax NVAX Price / book

Price / book at other companies

Moderna logo
ModernaMRNA
4.1×+3.0×
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
2.8×+1.3×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
ALN
Alnylam PharmaceuticalsALNY
29.7×-139×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
Gilead Sciences logo
Gilead SciencesGILD
13.4×+6.6×

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.2B+10.1%
Enterprise value$1.27B+41.6%
P/S2×+1.0×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.5×+0.4×

Where this comes from

Calculated from Novavax’s reported figures.

market cap/total stockholders equity=27.9×

Based on the most recent quarter.

The source filing: Novavax’s 10-Q, filed August 6, 2025. Open the filing →

Filed
Aug 6, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001000694-25-000029

FAQ

What is Novavax's price / book?
Novavax (NVAX) reported price / book of 27.9× in Q2 2025.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Novavax's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude